Émilie Orlhac

The ALS Society of Canada is proud to announce the funding of a 2025 ALS Canada Discovery Grant in partnership with the ALS Québec – Dr. Jean-Pierre Canuel Fund, to support a research project led by Dr. Janice Robertson at the University of Toronto. The one-year, $125,000 grant will support Dr. Robertson and her team’s project, Mapping Alternative Polyadenylation and Splicing in ALS via...

Special golf experiences up for bid as Quebec’s golf community tees off to support ALS Quebec MONTRÉAL, August 5th, 2025 — One year after its impactful launch, United on the Greens to End ALS is returning to Quebec this year. Uniting Quebec’s golf community in support of families affected by amyotrophic lateral sclerosis (ALS), the province-wide fundraising initiative invites golf...

Health Canada has agreed to review a New Drug Submission (NDS) for Tofersen, for the treatment of amyotrophic lateral sclerosis (ALS) in adults with a mutation in the superoxide dismutase 1 (SOD1) gene. A regulatory decision on the New Drug Submission is expected in early 2025. If approved, this therapy will become the first treatment in Canada to target a genetic cause of ALS. Read the...